Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures
Authors:
- 1 August 2011
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (8) , 3795-3802
Abstract
The exceptionalin vitropotency of the hepatitis C virus (HCV) NS5A inhibitor BMS-790052 has translated into anin vivoeffect in proof-of-concept clinical trials. Although the 50% effective concentration (EC50) of the initial lead, the thiazolidinone BMS-824, was ∼10 nM in the replicon assay, it underwent transformation to other inhibitory species after incubation in cell culture medium. The biological profile of BMS-824, including the EC50, the drug concentration required to reduce cell growth by 50% (CC50), and the resistance profile, however, remained unchanged, triggering an investigation to identify the biologically active species. High-performance liquid chromatography (HPLC) biogram fractionation of a sample of BMS-824 incubated in medium revealed that the most active fractions could readily be separated from the parental compound and retained the biological profile of BMS-824. From mass spectral and nuclear magnetic resonance data, the active species was determined to be a dimer of BMS-824 derived from an intermolecular radical-mediated reaction of the parent compound. Based upon an analysis of the structural elements of the dimer deemed necessary for anti-HCV activity, the stilbene derivative BMS-346 was synthesized. This compound exhibited excellent anti-HCV activity and showed a resistance profile similar to that of BMS-824, with changes in compound sensitivity mapped to the N terminus of NS5A. The N terminus of NS5A has been crystallized as a dimer, complementing the symmetry of BMS-346 and allowing a potential mode of inhibition of NS5A to be discussed. Identification of the stable, active pharmacophore associated with these NS5A inhibitors provided the foundation for the design of more potent inhibitors with broad genotype inhibition. This culminated in the identification of BMS-790052, a compound that preserves the symmetry discovered with BMS-346.Keywords
This publication has 20 references indexed in Scilit:
- Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical StilbenesACS Medicinal Chemistry Letters, 2011
- Identification of Hepatitis C Virus NS5A InhibitorsJournal of Virology, 2010
- Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C VirusJournal of Virology, 2009
- Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicaseNature, 2005
- Development of a Cell-Based High-Throughput Specificity Screen Using a Hepatitis C Virus-Bovine Viral Diarrhea Virus Dual Replicon AssayAntimicrobial Agents and Chemotherapy, 2005
- Hepatitis C virus NS5A: tales of a promiscuous proteinJournal of General Virology, 2004
- Structure and Function of the Membrane Anchor Domain of Hepatitis C Virus Nonstructural Protein 5AJournal of Biological Chemistry, 2004
- Efficient Initiation of HCV RNA Replication in Cell CultureScience, 2000
- Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell LineScience, 1999
- Production of Two Phosphoproteins from the NS5A Region of the Hepatitis C Viral GenomeBiochemical and Biophysical Research Communications, 1994